izpis_h1_title_alt

A prospective phase II study evaluating intraoperative electrochemotherapy of hepatocellular carcinoma
ID Djokić, Mihajlo (Avtor), ID Čemažar, Maja (Avtor), ID Omerzel, Maša (Avtor), ID Dežman, Rok (Avtor), ID Badovinac, David (Avtor), ID Miklavčič, Damijan (Avtor), ID Kos, Bor (Avtor), ID Štabuc, Miha (Avtor), ID Štabuc, Borut (Avtor), ID Janša, Rado (Avtor), ID Popović, Peter (Avtor), ID Šmid, Lojze (Avtor), ID Serša, Gregor (Avtor), ID Trotovšek, Blaž (Avtor)

.pdfPDF - Predstavitvena datoteka, prenos (11,93 MB)
MD5: 2D64E62A853DA73CB9748CC10EE3A466
URLURL - Izvorni URL, za dostop obiščite https://www.mdpi.com/2072-6694/12/12/3778 Povezava se odpre v novem oknu

Izvleček
The aim of this clinical study was to investigate the effectiveness and long-term safety of electrochemotherapy as an emerging treatment for HCC in patients not suitable for other treatment options. A prospective phase II clinical study was conducted in patients with primary HCC who were not suitable for other treatment options according to the Barcelona Clinic Liver Cancer classification. A total of 24 patients with 32 tumors were treated by electrochemotherapy. The procedure was effective, feasible, and safe with some procedure-related side effects. The responses of the 32 treated nodules were: 84.4% complete response (CR), 12.5% partial response (PR), and 3.1% stable disease (SD). The treatment was equally effective for nodules located centrally and peripherally. Electrochemotherapy provided a durable response with local tumor control over 50 months of observation in 78.0% of nodules. The patient responses were: 79.2% CR and 16.6% PR. The median progression-free survival was 12 months (range 2.7–50), and the overall survival over 5 years of observation was 72.0%. This prospective phase II clinical study showed that electrochemotherapy was an effective, feasible, and safe option for treating HCC in patients not suitable for other treatment options.

Jezik:Angleški jezik
Ključne besede:electrochemotherapy, hepatocellular carcinoma, open surgery, liver cancer, bleomycin
Vrsta gradiva:Članek v reviji
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:MF - Medicinska fakulteta
FE - Fakulteta za elektrotehniko
ZF - Zdravstvena fakulteta
Status publikacije:Objavljeno
Različica publikacije:Objavljena publikacija
Leto izida:2020
Št. strani:14 str.
Številčenje:Vol. 12, iss. 12, art. 3778
PID:20.500.12556/RUL-134836 Povezava se odpre v novem oknu
UDK:602
ISSN pri članku:2072-6694
DOI:10.3390/cancers12123778 Povezava se odpre v novem oknu
COBISS.SI-ID:42834691 Povezava se odpre v novem oknu
Datum objave v RUL:03.02.2022
Število ogledov:1498
Število prenosov:348
Metapodatki:XML DC-XML DC-RDF
:
Kopiraj citat
Objavi na:Bookmark and Share

Gradivo je del revije

Naslov:Cancers
Skrajšan naslov:Cancers
Založnik:MDPI
ISSN:2072-6694
COBISS.SI-ID:517914137 Povezava se odpre v novem oknu

Licence

Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.
Začetek licenciranja:15.12.2020

Sekundarni jezik

Jezik:Slovenski jezik
Ključne besede:elektrokemoterapija, hepatocelularni rak, kirurgija

Projekti

Financer:ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
Številka projekta:P3-0003
Naslov:Razvoj in ovrednotenje novih terapij za zdravljenje malignih tumorjev

Financer:ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
Številka projekta:P2-0249
Naslov:Elektroporacija v biologiji, biotehnologiji in medicini

Financer:Drugi - Drug financer ali več financerjev
Program financ.:University Clinical Center Ljubljana
Številka projekta:20180061

Podobna dela

Podobna dela v RUL:
Podobna dela v drugih slovenskih zbirkah:

Nazaj